Clinical trials
Every registered trial of Pramlintide
60 studies, 4 still enrolling.
Plain-Language Summary
Plain-language reading of the public trial registries.
In short
- Pramlintide has a real but limited body of human research.
- 60 registered studies in total.
- 4 are still enrolling people, so this is active research, not just history.
What kind of research
- 59 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
- About 4,559 people took part in those.
- A further 1 study only looked at records of people already taking it. These are counted separately because nobody was given the peptide for the study, so they cannot prove cause and effect.
How far along it is
- 18 trials have reached phase 3 or 4 — the large, late-stage trials regulators rely on to approve a drug.
- 19 have published results in the medical literature that anyone can read.
- The research spans 5 countries.
A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.
Filter
Showing 60 of 60 trials for Pramlintide.
Postprandial Regulation of Bone Perfusion in Healthy Individuals
University of Copenhagen
Healthy Adult Participants · Bone Physiology · Bone Blood Flow Regulation · Peptide Hormones
Pancreatic Polypeptide as a Modulator of Amylin- Induced Satiety in Healthy Humans
University Hospital, Gentofte, Copenhagen
Obesity & Overweight
Amylin-Induced Migraine Attacks Without Aura
Danish Headache Center
Headache Disorders, Primary · Headache Disorders · Brain Diseases · Nervous System Diseases
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Hypersensitivity to Amylin in Post-Traumatic Headache
Danish Headache Center
Headache Disorders, Secondary · Brain Diseases · Headache Disorders · Nervous System Diseases
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Tailoring Obesity Treatment Trial
Esbjerg Hospital - University Hospital of Southern Denmark
Obesity · Appetite Regulation · PreDiabetes
Two Way Crossover Closed Loop Study Insulin vs Insulin and Pramlintide
Oregon Health and Science University
Type 1 Diabetes
The Role of Amylin in Bone Metabolism
Filip Krag Knop
Bone Diseases, Metabolic · Type 1 Diabetes
A Fully Automated Lyumjev and Pramlintide Delivery System for Adults With Type 1 Diabetes
McGill University Health Centre/Research Institute of the McGill University Health Centre
type1diabetes · Diabetes Mellitus, Type 1
A Fully-closed Loop, Pramlintide and Insulin, Artificial Pancreas Clinical Trial for Adults With Type 1 Diabetes
McGill University Health Centre/Research Institute of the McGill University Health Centre
Type 1 Diabetes
Co-administration of Pramlintide and Insulin Via an Automated Dual-hormone Artificial Pancreas System in Adults With Type 1 Diabetes
McGill University
Diabetes Mellitus, Type 1 · Type 1 Diabetes · Postprandial Hyperglycemia
Alleviating Carbohydrate Counting for Patients With Type 1 Diabetes Using a Novel Insulin-plus-pramlintide Artificial Pancreas
McGill University
Type 1 Diabetes · Type 1 Diabetes Mellitus · Hyperglycemia, Postprandial
Multi-Center Development of a Novel Diagnostic Test for Alzheimer's Disease
Boston University
Alzheimer Disease · Mild Cognitive Impairment
Biological Outcomes of Pramlintide in Resectable Cutaneous Squamous Cell Carcinoma: A Pilot Study
H. Lee Moffitt Cancer Center and Research Institute
Cutaneous Squamous Cell Carcinoma
Phase 2, Randomized, Open-Label, Crossover, PD/PK Study of a Novel Pram-Insulin Co-Formulation in Adults With T1D
Xeris Pharmaceuticals
Diabetes Mellitus, Type 1 · Insulin-dependent Diabetes Mellitus
Pramlintide and Fiasp Closed-Loop With a Simple Meal Announcement
McGill University
Type 1 Diabetes Mellitus
Insulin-plus-pramlintide Closed-loop Strategy to Regulate Glucose Levels Without Carbohydrate Counting
McGill University
Diabetes Mellitus, Type 1
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
A Trial to Assess a Co-formulation of an Insulin Analog and Pramlintide in Subjects With Type 1 Diabetes Mellitus
Adocia
Type 1 Diabetes Mellitus
Amylin and CGRP Head to Head Provocation in Migraine Without Aura Patients
Danish Headache Center
Migraine Without Aura
Glucagon Counterregulation in Type 1 Diabetes
University of Virginia
Type 1 Diabetes Mellitus
Effect of Basal-Bolus Closed-Loop Co-Administration of Insulin and Pramlintide on Improving the Glycemic Control in Type 1 Diabetes
McGill University
Diabetes Mellitus, Type 1
Named in the study description rather than as the headline intervention — often a drug given alongside the one being tested.
Effect of a Fixed Pramlintide: Insulin Dose Ratio on Postprandial Glucose in Type 1 Diabetes Mellitus
AstraZeneca
Type 1 Diabetes Mellitus
Phase 2 Study of Adaptive Insulin Meal Supervisor (AIMS) in Adults With Type 1 Diabetes Mellitus
University of Virginia
Diabetes Mellitus, Type 1
Effect of Different Fixed Pramlintide:Insulin Dose Ratios on Postprandial Glucose in T1DM
AstraZeneca
Type 1 Diabetes
Pramlintide Combined With Model Predictive Control Algorithm
University of Virginia
Type 1 Diabetes Mellitus
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
AstraZeneca
Obesity
Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus
Cheryl Rosenfeld, DO
Type 2 Diabetes Mellitus
Pramlintide (Symlin) for the Treatment of Hypoglycemia Following Gastric Bypass Surgery
Joslin Diabetes Center
Hypoglycemia · Evidence of Previous Gastric Surgery
Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia
Albert Einstein College of Medicine
Type 1 Diabetes
Effectiveness Study of Pramlintide to Treat Post-Transplant Diabetes Mellitus
University of Colorado, Denver
Diabetes Mellitus
The Effect of Byetta and Symlin on Post-meal Meal Blood Sugar Levels in Children With Type 2 Diabetes
Baylor College of Medicine
Type 2 Diabetes
Effects of Pramlintide on Endogenous Production of Very-low-density-lipoprotein (VLDL)-Triglyceride and Glucose in the Post Prandial State in T2DM
University of Maryland, Baltimore
Type 2 Diabetes
Extension Study of Protocol DFA102 to Examine the Long-Term Safety, Tolerability, and Effect on Body Weight of Pramlintide Administered in Combination With Metreleptin
AstraZeneca
Obesity
Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects
AstraZeneca
Overweight · Obesity
Demonstrate the Effects of Pramlintide on Weight Reduction in Schizophrenia
University of Texas Southwestern Medical Center
Schizophrenia · Schizoaffective Disorder · Diabetes · Weight Gain
The Effect of Pramlintide on Meal Time Insulin Bolus
Diabetes Care Center
Type 1 Diabetes
A Pilot Study of Continuous Subcutaneous Pramlintide Infusion Therapy in Patients With Type 1 Diabetes
University Diabetes & Endocrine Consultants
IDDM
Efficacy of Pramlintide on Prevention of Weight Gain Early Onset of Type 1 Diabetes
University of Texas Southwestern Medical Center
Type 1 Diabetes
A Study to Characterize Regimens of Basal Insulin Intensified With Either Symlin® or Rapid Acting Insulin in Patients With Type 2 Diabetes
AstraZeneca
Type 2 Diabetes Mellitus
Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus
Montefiore Medical Center
Type 1 Diabetes Mellitus
Pramlintide in Adolescents With Type 1 Diabetes
University of Colorado, Denver
Type 1 Diabetes
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
AstraZeneca
Overweight · Obesity
A Study to Evaluate the Effect on Body Weight of Leptin Administered in Conjunction With Pramlintide in Overweight and Obese Subjects
AstraZeneca
Overweight · Obesity
A Study to Evaluate Symlin in Adolescent Subjects With Type 1 Diabetes Mellitus
AstraZeneca
Type 1 Diabetes Mellitus
Continuous Subcutaneous Infusion of Pramlintide and Insulin
Baylor College of Medicine
Type 1 Diabetes
A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide
Oregon Health and Science University
Obesity
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
AstraZeneca
Type 2 Diabetes Mellitus
A Study to Examine the Long Term Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
AstraZeneca
Obesity
An Observational Study Evaluating SYMLIN® (Pramlintide Acetate) Injection Use in Insulin Using Patients With Type 2 and Type 1 Diabetes
AstraZeneca
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
A Study to Examine the Effect of Pramlintide on Body Weight and Its Safety and Tolerability in Obese Subjects
AstraZeneca
Obesity
Effect of Hyperglycemia on Gastric Emptying Interactions With Pramlintide
Ludwig-Maximilians - University of Munich
Type 1 Diabetes
Exploratory Study to Evaluate Various Pharmacodynamic Effects of Subcutaneously Infused or Injected Pramlintide in Obese Subjects
AstraZeneca
Overweight · Obesity
The Effect of Prolonged Pramlintide Infusion in Pediatric Diabetes
Baylor College of Medicine
Type 1 Diabetes
Clinical Utility and Safety of Pramlintide in Subjects With Type 1 and Type 2 Diabetes Mellitus
AstraZeneca
Type 1 Diabetes Mellitus · Type 2 Diabetes Mellitus
Study of the Long-Term Safety of Pramlintide in Subjects With Type 1 Diabetes Mellitus
AstraZeneca
Diabetes Mellitus, Type 1
Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide
AstraZeneca
Diabetes Mellitus, Non-Insulin-Dependent
Evaluation of the Effect of Pramlintide on Satiety and Food Intake
AstraZeneca
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
The Role of Amylin and Glucagon in T1DM
Baylor College of Medicine
Type 1 Diabetes
Evaluation of the Bioavailability of Pramlintide
AstraZeneca
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control
AstraZeneca
Diabetes Mellitus, Type 1
The impact of pramlintide on top of semaglutide in obese people with prediabetes
Esbjerg Sygehus
Obesity (BMI ≧ 30kg/m2), Pre-diabetes (HbA1c 39-47 mmol/mol)
Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Pramlintide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.